UniProt P30291 · PDB · AlphaFold · Substrate: CDK1 (D146N)/cyclin B1 · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 60.0% | 40.0% | 87.22 | 0.555 |
| 2 | Dasatinib | 46.1% | 53.9% | 87.97 | 0.699 |
| 3 | Midostaurin | 30.3% | 69.7% | 78.64 | 0.500 |
| 4 | Brigatinib | 25.8% | 74.2% | 82.96 | 0.513 |
| 5 | Sunitinib | 25.7% | 74.3% | 91.73 | 0.524 |
| 6 | Vemurafenib | 20.8% | 79.2% | 96.49 | 0.598 |
| 7 | Gilteritinib | 19.1% | 80.9% | 88.97 | 0.506 |
| 8 | Nintedanib | 18.7% | 81.3% | 90.23 | 0.608 |
| 9 | Everolimus | 17.6% | 82.4% | 100.00 | 0.706 |
| 10 | Netarsudil | 16.9% | 83.1% | 93.22 | 0.676 |
| 11 | Acalabrutinib | 16.5% | 83.5% | 99.50 | 0.670 |
| 12 | Lapatinib | 16.2% | 83.8% | 99.25 | 0.616 |
| 13 | Afatinib | 16.0% | 84.0% | 98.50 | 0.709 |
| 14 | Regorafenib | 15.9% | 84.1% | 95.99 | 0.719 |
| 15 | Dacomitinib | 14.4% | 85.6% | 97.99 | 0.664 |
| 16 | Temsirolimus | 14.1% | 85.9% | 100.00 | 0.740 |
| 17 | Tofacitinib | 13.6% | 86.4% | 99.25 | 0.684 |
| 18 | Nilotinib | 13.5% | 86.5% | 96.49 | 0.765 |
| 19 | Erlotinib | 13.1% | 86.9% | 99.75 | 0.695 |
| 20 | Sirolimus | 12.8% | 87.2% | 100.00 | 0.708 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.45
- Epithelial log2(TPM+1): 4.52
- Fold change: -0.07
- Status: No significant change
Selectivity landscape vs inhibition on WEE1
Each point is one of the 92 approved drugs; color = inhibition % on WEE1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…